UnknownPhase 3NCT00006045

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia

Studying Acute erythroid leukemia

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Facet Biotech
Principal Investigator: Daniel Levitt, MD, PhD, MD
Facet Biotech
Intervention: lintuzumab(biological)
Eligibility: 18 years · All sexes
Timeline: 2000

Study locations (30)

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Beckman Research Institute, City of Hope, Los Angeles, California, United States
St. Joseph Hospital - Orange, Orange, California, United States
Sutter Cancer Center, Sacramento, California, United States
University of California Davis Cancer Center, Sacramento, California, United States
Sidney Kimmel Cancer Center, San Diego, California, United States
Washington Cancer Institute, Washington D.C., District of Columbia, United States
Emory Clinic, Atlanta, Georgia, United States
University of Illinois at Chicago, Chicago, Illinois, United States
Loyola University Medical Center, Maywood, Illinois, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Louisiana State University School of Medicine, Shreveport, Louisiana, United States
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
New England Medical Center Hospital, Boston, Massachusetts, United States
+15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00006045 on ClinicalTrials.gov

Other trials for Acute erythroid leukemia

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE2NCT00658814
Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)

See all trials for Acute erythroid leukemia →

← Back to all trials